Information Technology Services
Build Your Comparison
Side-by-side financial analysisStock Comparison
WAY vs VEEV vs DOCS vs CRM vs KO
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
Medical - Healthcare Information Services
Software - Application
Beverages - Non-Alcoholic
WAY vs VEEV vs DOCS vs CRM vs KO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Information Technology Services | Medical - Healthcare Information Services | Medical - Healthcare Information Services | Software - Application | Beverages - Non-Alcoholic |
| Market Cap | $3.60B | $25.92B | $3.75B | $135.86B | $355.61B |
| Revenue (TTM) | $1.16B | $3.32B | $645M | $42.83B | $49.28B |
| Net Income (TTM) | $126M | $942M | $196M | $8.02B | $13.70B |
| Gross Margin | 65.2% | 75.0% | 89.1% | 77.6% | 61.7% |
| Operating Margin | 24.3% | 28.8% | 33.3% | 21.9% | 29.3% |
| Forward P/E | 11.4x | 17.6x | 14.0x | 14.1x | 25.3x |
| Total Debt | $1.50B | $96M | $10M | $17.18B | $45.49B |
| Cash & Equiv. | $61M | $1.42B | $219M | $7.33B | $10.27B |
WAY vs VEEV vs DOCS vs CRM vs KO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 24 | Jun 26 | Return |
|---|---|---|---|
| Waystar Holding Cor… (WAY) | 100 | 87.2 | -12.8% |
| Veeva Systems Inc. (VEEV) | 100 | 87.2 | -12.8% |
| Doximity, Inc. (DOCS) | 100 | 71.6 | -28.4% |
| Salesforce, Inc. (CRM) | 100 | 64.5 | -35.5% |
| The Coca-Cola Compa… (KO) | 100 | 129.8 | +29.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: WAY vs VEEV vs DOCS vs CRM vs KO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
WAY has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 16.5%, EPS growth 5.7%, 3Y rev CAGR 16.0%
- 16.5% revenue growth vs KO's 1.9%
- Lower P/E (11.4x vs 25.3x)
VEEV is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.69, Low D/E 1.3%, current ratio 4.89x
DOCS is the #2 pick in this set and the best alternative if valuation efficiency is your priority.
- PEG 0.27 vs KO's 2.26
- 30.4% margin vs WAY's 10.9%
- 16.5% ROA vs WAY's 2.4%, ROIC 19.8% vs 4.2%
CRM is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 2 yrs, beta 0.64, yield 1.0%
- Beta 0.64, yield 1.0%, current ratio 0.76x
- Beta 0.64 vs WAY's 0.84, lower leverage
KO ranks third and is worth considering specifically for long-term compounding.
- 121.1% 10Y total return vs VEEV's 367.2%
- 2.5% yield, 56-year raise streak, vs CRM's 1.0%, (3 stocks pay no dividend)
- +17.2% vs DOCS's -64.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.5% revenue growth vs KO's 1.9% | |
| Value | Lower P/E (11.4x vs 25.3x) | |
| Quality / Margins | 30.4% margin vs WAY's 10.9% | |
| Stability / Safety | Beta 0.64 vs WAY's 0.84, lower leverage | |
| Dividends | 2.5% yield, 56-year raise streak, vs CRM's 1.0%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +17.2% vs DOCS's -64.8% | |
| Efficiency (ROA) | 16.5% ROA vs WAY's 2.4%, ROIC 19.8% vs 4.2% |
WAY vs VEEV vs DOCS vs CRM vs KO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
WAY vs VEEV vs DOCS vs CRM vs KO — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
KO leads in 3 of 6 categories
DOCS leads 2 • WAY leads 1 • VEEV leads 0 • CRM leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
DOCS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KO is the larger business by revenue, generating $49.3B annually — 76.4x DOCS's $645M. DOCS is the more profitable business, keeping 30.4% of every revenue dollar as net income compared to WAY's 10.9%. On growth, WAY holds the edge at +22.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.2B | $3.3B | $645M | $42.8B | $49.3B |
| EBITDAEarnings before interest/tax | $430M | $1.1B | $227M | $12.2B | $15.5B |
| Net IncomeAfter-tax profit | $126M | $942M | $196M | $8.0B | $13.7B |
| Free Cash FlowCash after capex | $294M | $518M | $215M | $14.7B | $12.6B |
| Gross MarginGross profit ÷ Revenue | +65.2% | +75.0% | +89.1% | +77.6% | +61.7% |
| Operating MarginEBIT ÷ Revenue | +24.3% | +28.8% | +33.3% | +21.9% | +29.3% |
| Net MarginNet income ÷ Revenue | +10.9% | +28.4% | +30.4% | +18.7% | +27.8% |
| FCF MarginFCF ÷ Revenue | +25.4% | +15.6% | +33.3% | +34.2% | +25.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.4% | +16.3% | +5.1% | +13.3% | +12.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +37.5% | +14.6% | -67.7% | +52.2% | +18.2% |
Valuation Metrics
WAY leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 20.4x trailing earnings, DOCS trades at a 33% valuation discount to WAY's 30.7x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.39x vs KO's 2.43x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $3.6B | $25.9B | $3.7B | $135.9B | $355.6B |
| Enterprise ValueMkt cap + debt − cash | $5.0B | $24.6B | $3.5B | $145.7B | $390.8B |
| Trailing P/EPrice ÷ TTM EPS | 30.74x | 29.33x | 20.45x | 21.27x | 27.18x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.42x | 17.61x | 13.99x | 14.09x | 25.27x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.61x | 0.39x | 1.74x | 2.43x |
| EV / EBITDAEnterprise value multiple | 12.39x | 20.59x | 16.47x | 11.61x | 26.39x |
| Price / SalesMarket cap ÷ Revenue | 3.27x | 8.11x | 5.81x | 3.27x | 7.42x |
| Price / BookPrice ÷ Book value/share | 0.95x | 3.69x | 4.20x | 2.68x | 10.40x |
| Price / FCFMarket cap ÷ FCF | 12.70x | 18.70x | — | 9.43x | 67.15x |
Profitability & Efficiency
DOCS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $4 for WAY. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), CRM scores 7/9 vs WAY's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +3.5% | +13.4% | +19.4% | +14.9% | +41.1% |
| ROA (TTM)Return on assets | +2.4% | +11.0% | +16.5% | +7.8% | +13.1% |
| ROICReturn on invested capital | +4.2% | +12.9% | +19.8% | +10.1% | +15.8% |
| ROCEReturn on capital employed | +5.2% | +13.8% | +20.7% | +11.9% | +17.3% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 6 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.39x | 0.01x | 0.01x | 0.29x | 1.33x |
| Net DebtTotal debt minus cash | $1.4B | -$1.3B | -$209M | $9.8B | $35.2B |
| Cash & Equiv.Liquid assets | $61M | $1.4B | $219M | $7.3B | $10.3B |
| Total DebtShort + long-term debt | $1.5B | $96M | $10M | $17.2B | $45.5B |
| Interest CoverageEBIT ÷ Interest expense | 3.51x | — | — | 21.32x | 10.70x |
Total Returns (Dividends Reinvested)
KO leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $3,781 for DOCS. Over the past 12 months, KO leads with a +17.2% total return vs DOCS's -64.8%. The 3-year compound annual growth rate (CAGR) favors KO at 13.7% vs DOCS's -15.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -40.2% | -27.3% | -53.7% | -34.2% | +20.3% |
| 1-Year ReturnPast 12 months | -52.6% | -43.5% | -64.8% | -37.1% | +17.2% |
| 3-Year ReturnCumulative with dividends | -9.4% | -16.2% | -38.7% | -20.4% | +47.0% |
| 5-Year ReturnCumulative with dividends | -9.4% | -47.5% | -62.2% | -31.0% | +65.6% |
| 10-Year ReturnCumulative with dividends | -9.4% | +367.2% | -62.2% | +108.7% | +121.1% |
| CAGR (3Y)Annualised 3-year return | -3.2% | -5.7% | -15.0% | -7.3% | +13.7% |
Risk & Volatility
KO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than WAY's 0.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs DOCS's 26.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.84x | 0.69x | 0.75x | 0.64x | -0.20x |
| 52-Week HighHighest price in past year | $41.47 | $310.50 | $76.51 | $276.80 | $84.04 |
| 52-Week LowLowest price in past year | $17.89 | $148.05 | $17.16 | $161.40 | $65.35 |
| % of 52W HighCurrent price vs 52-week peak | +45.2% | +51.4% | +26.2% | +59.9% | +98.3% |
| RSI (14)Momentum oscillator 0–100 | 40.3 | 43.8 | 40.7 | 38.9 | 60.6 |
| Avg Volume (50D)Average daily shares traded | 2.4M | 2.3M | 3.9M | 12.5M | 12.7M |
Analyst Outlook
KO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: WAY as "Buy", VEEV as "Buy", DOCS as "Hold", CRM as "Buy", KO as "Buy". Consensus price targets imply 90.0% upside for WAY (target: $36) vs 4.2% for KO (target: $86). For income investors, KO offers the higher dividend yield at 2.46% vs CRM's 1.00%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $35.62 | $235.38 | $29.47 | $265.75 | $86.13 |
| # AnalystsCovering analysts | 17 | 43 | 23 | 97 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +1.0% | +2.5% |
| Dividend StreakConsecutive years of raises | — | 0 | — | 2 | 56 |
| Dividend / ShareAnnual DPS | — | — | — | $1.66 | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.7% | +11.5% | +9.3% | +0.2% |
KO leads in 3 of 6 categories (Total Returns, Risk & Volatility). DOCS leads in 2 (Income & Cash Flow, Profitability & Efficiency).
WAY vs VEEV vs DOCS vs CRM vs KO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is WAY or VEEV or DOCS or CRM or KO a better buy right now?
For growth investors, Waystar Holding Corp.
(WAY) is the stronger pick with 16. 5% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). Doximity, Inc. (DOCS) offers the better valuation at 20. 4x trailing P/E (14. 0x forward), making it the more compelling value choice. Analysts rate Waystar Holding Corp. (WAY) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — WAY or VEEV or DOCS or CRM or KO?
On trailing P/E, Doximity, Inc.
(DOCS) is the cheapest at 20. 4x versus Waystar Holding Corp. at 30. 7x. On forward P/E, Waystar Holding Corp. is actually cheaper at 11. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 27x versus The Coca-Cola Company's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — WAY or VEEV or DOCS or CRM or KO?
Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.
6%, compared to -62. 2% for Doximity, Inc. (DOCS). Over 10 years, the gap is even starker: VEEV returned +367. 2% versus DOCS's -62. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — WAY or VEEV or DOCS or CRM or KO?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
20β versus Waystar Holding Corp. 's 0. 84β — meaning WAY is approximately -520% more volatile than KO relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.
05Which is growing faster — WAY or VEEV or DOCS or CRM or KO?
By revenue growth (latest reported year), Waystar Holding Corp.
(WAY) is pulling ahead at 16. 5% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: Waystar Holding Corp. grew EPS 569. 2% year-over-year, compared to -11. 7% for Doximity, Inc.. Over a 3-year CAGR, WAY leads at 16. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — WAY or VEEV or DOCS or CRM or KO?
Doximity, Inc.
(DOCS) is the more profitable company, earning 30. 4% net margin versus 10. 2% for Waystar Holding Corp. — meaning it keeps 30. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 33. 3% versus 21. 5% for CRM. At the gross margin level — before operating expenses — DOCS leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is WAY or VEEV or DOCS or CRM or KO more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 27x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Waystar Holding Corp. (WAY) trades at 11. 4x forward P/E versus 25. 3x for The Coca-Cola Company — 13. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for WAY: 90. 0% to $35. 62.
08Which pays a better dividend — WAY or VEEV or DOCS or CRM or KO?
In this comparison, KO (2.
5% yield), CRM (1. 0% yield) pay a dividend. WAY, VEEV, DOCS do not pay a meaningful dividend and should not be held primarily for income.
09Is WAY or VEEV or DOCS or CRM or KO better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
20), 2. 5% yield, +121. 1% 10Y return). Both have compounded well over 10 years (KO: +121. 1%, WAY: -9. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between WAY and VEEV and DOCS and CRM and KO?
These companies operate in different sectors (WAY (Technology) and VEEV (Healthcare) and DOCS (Healthcare) and CRM (Technology) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: WAY is a small-cap high-growth stock; VEEV is a mid-cap high-growth stock; DOCS is a small-cap quality compounder stock; CRM is a mid-cap quality compounder stock; KO is a large-cap quality compounder stock. CRM, KO pay a dividend while WAY, VEEV, DOCS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.